102
Participants
Start Date
October 31, 2016
Primary Completion Date
April 30, 2027
Study Completion Date
August 31, 2041
Leuprolide Acetate
Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Goserelin Acetate
Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Triptorelin
Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Enzalutamide
Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
Stereotactic Body Radiation Therapy
Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
BC CANCER Vancouver, Vancouver
CancerCare Manitoba, Winnipeg
Nova Scotia Cancer Centre, Halifax
Juravinski Cancer Centre, Hamilton
London Regional Cancer Program - London Health Sciences Centre, London
Hopital Charles-Lemoyne, Longueuil
Centre Hospitalier de l'Université de Montréal (CHUM) - Hopital Notre Dame, Montreal
Jewish General Hospital, McGill University, Montreal
McGill University Health Center, Montreal
CHU de Quebec-Universite Laval, Québec
Centre Hospitalier régional de Trois-Rivières, Trois-Rivières
Sir Mortimer B. Davis - Jewish General Hospital
OTHER